| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(16)30066-3 |
| P698 | PubMed publication ID | 27247226 |
| P50 | author | Tanguy Y Seiwert | Q89776148 |
| P2093 | author name string | Jonathan D Cheng | |
| Jared Weiss | |||
| Raanan Berger | |||
| Terrill McClanahan | |||
| Karl Heath | |||
| Barbara Burtness | |||
| Ranee Mehra | |||
| Christine Gause | |||
| Laura Q Chow | |||
| Jared Lunceford | |||
| Joseph Paul Eder | |||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Trial watch: IDO inhibitors in cancer therapy | Q27006866 | ||
| Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials | Q27853003 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| PD-L2 is a second ligand for PD-1 and inhibits T cell activation | Q28202471 | ||
| PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2 | Q28202803 | ||
| Comprehensive genomic characterization of head and neck squamous cell carcinomas | Q28256121 | ||
| Direct multiplexed measurement of gene expression with color-coded probe pairs | Q29614417 | ||
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas | Q35008028 | ||
| Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis | Q35541507 | ||
| Pseudoprogression and Immune-Related Response in Solid Tumors | Q36211586 | ||
| The chemoradiation paradigm in head and neck cancer | Q36747213 | ||
| Index for rating diagnostic tests | Q39605675 | ||
| Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes | Q41607812 | ||
| Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma | Q41980925 | ||
| Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing. | Q51798238 | ||
| Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base | Q57949385 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| pembrolizumab | Q13896859 | ||
| head and neck squamous cell carcinoma | Q18348812 | ||
| metastatic squamous cell carcinoma | Q18975728 | ||
| P304 | page(s) | 956-965 | |
| P577 | publication date | 2016-05-27 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial | |
| P478 | volume | 17 |
| Q90656338 | (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer |
| Q39186868 | 3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes. |
| Q90287047 | A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers |
| Q41928232 | A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response? |
| Q50027076 | A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma |
| Q92157000 | A gene signature associated with prognosis and immune processes in head and neck squamous cell carcinoma |
| Q92974648 | A good start of immunotherapy in esophageal cancer |
| Q92133160 | A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma |
| Q39124696 | A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. |
| Q64091981 | A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) |
| Q93115091 | A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer |
| Q89776150 | A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma |
| Q55092262 | A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. |
| Q92016091 | A systematic analysis of immune genes and overall survival in cancer patients |
| Q48240243 | AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. |
| Q89457684 | ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer |
| Q57177466 | Acquired resistance to cancer immunotherapy |
| Q58785196 | Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide |
| Q58695217 | Activation of viral defense signaling in cancer |
| Q41925180 | Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer |
| Q47097238 | Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma |
| Q89821073 | Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma |
| Q102152216 | An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC |
| Q28079132 | An update on larynx cancer |
| Q58095080 | An update: emerging drugs to treat squamous cell carcinomas of the head and neck |
| Q99546826 | Analysis of chemotherapy effect on the second primary malignancy for head and neck cancer patients by a nomogram based on SEER database |
| Q58567297 | Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer |
| Q54982410 | Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO). |
| Q51079342 | Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ. |
| Q92586182 | Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape |
| Q88369444 | Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo |
| Q38959172 | Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. |
| Q92796464 | Application of PD-1 Blockade in Cancer Immunotherapy |
| Q46540302 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Ca |
| Q54685474 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I |
| Q47236231 | Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care |
| Q58491112 | Autoimmune pancerebellitis associated with pembrolizumab therapy |
| Q90468882 | B-cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade |
| Q93099672 | B7-1 drives TGF-β stimulated pancreatic carcinoma cell migration and expression of EMT target genes |
| Q90053621 | Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma |
| Q48289963 | Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. |
| Q47359765 | Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy |
| Q93054476 | Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation |
| Q39190801 | Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma |
| Q38896144 | Biological predictors of radiosensitivity in head and neck squamous cell carcinoma |
| Q59611470 | Biomarker driven treatment of head and neck squamous cell cancer |
| Q90226660 | Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization |
| Q91433225 | Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials |
| Q38679662 | Cancer Immunotherapies: Are They as Effective in the Elderly? |
| Q38737924 | Cancer Immunotherapy: Whence and Whither |
| Q89910962 | Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection |
| Q92619627 | Cardiac Metastasis in a Patient with Head and Neck Cancer: A Case Report and Review of the Literature |
| Q94526290 | Cautious optimism-the current role of immunotherapy in gastrointestinal cancers |
| Q92737181 | Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial |
| Q52582301 | Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. |
| Q92527773 | Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| Q50231313 | Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies |
| Q47164059 | Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? |
| Q47095674 | Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma |
| Q58576243 | Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy? |
| Q53098427 | Checkpoint immunotherapy in head and neck cancers. |
| Q38672084 | Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy |
| Q54988181 | Checkpoint inhibitors in the treatment of urological malignancies. |
| Q50021063 | Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review |
| Q92061967 | Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab - Diagnostic and Therapeutic Challenge: A Case Report |
| Q89811611 | Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma |
| Q98177744 | Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective |
| Q92626565 | Clinical and economic burden of head and neck cancer: a nationwide retrospective cohort study from France |
| Q50957199 | Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. |
| Q61798878 | Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury |
| Q59789596 | Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies |
| Q47860989 | Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. |
| Q91902169 | Clinical update on head and neck cancer: molecular biology and ongoing challenges |
| Q64983989 | Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. |
| Q49414583 | Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review |
| Q37742485 | Clusterization in head and neck squamous carcinomas based on lncRNA expression: molecular and clinical correlates. |
| Q64097320 | Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy |
| Q59351645 | Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial |
| Q88984924 | Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma |
| Q64279153 | Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma |
| Q91906078 | Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases |
| Q53740080 | Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. |
| Q47683846 | Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas |
| Q91892613 | Comprehensive immunogenomic landscape analysis of prognosis-related genes in head and neck cancer |
| Q59356808 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer |
| Q88051175 | Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer |
| Q38818008 | Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC. |
| Q28076294 | Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment |
| Q93039741 | Current Development of Monoclonal Antibodies in Cancer Therapy |
| Q37629874 | Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy |
| Q39389346 | Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers |
| Q90413950 | Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer |
| Q97527427 | Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective |
| Q39084115 | Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva |
| Q56890243 | Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors |
| Q59135385 | Current landscape of immune therapy in treatment of solid tumours, with future opportunities and challenges |
| Q38808580 | Current studies of immunotherapy in head and neck cancer |
| Q60958246 | Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer |
| Q90714354 | DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers |
| Q47326952 | De-novo and acquired resistance to immune checkpoint targeting. |
| Q93000860 | Design and Synthesis of Arf1-Targeting γ-Dipeptides as Potential Agents against Head and Neck Squamous Cell Carcinoma |
| Q56334001 | Design considerations for early-phase clinical trials of immune-oncology agents |
| Q59352525 | Detailed analysis of adenosine A2a receptor () and CD73 (5'-nucleotidase, ecto, ) methylation and gene expression in head and neck squamous cell carcinoma patients |
| Q47718879 | Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations |
| Q57295962 | Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) |
| Q46891217 | Does chemoselection open the door for immunotherapy? |
| Q53173327 | Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. |
| Q50020853 | Drug development in the era of precision medicine. |
| Q39069273 | Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. |
| Q98222326 | EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma |
| Q92259397 | ERK Activation Modulates Cancer Stemness and Motility of a Novel Mouse Oral Squamous Cell Carcinoma Cell Line |
| Q49842557 | ESMO-Magnitude of Clinical Benefit Scale version 1.1. |
| Q90353958 | Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States |
| Q52649584 | Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis. |
| Q89326677 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 |
| Q98164819 | Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials |
| Q100739241 | Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria |
| Q47399053 | Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment |
| Q33617949 | Emerging therapies for breast cancer |
| Q54256927 | Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer. |
| Q92072354 | Enhanced Radiation Sensitivity of Human Papillomavirus-Driven Head and Neck Cancer: Focus on Immunological Aspects |
| Q47391699 | Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. |
| Q52580666 | Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. |
| Q54116465 | Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. |
| Q38779793 | Evaluation of dosing strategy for pembrolizumab for oncology indications |
| Q59357202 | Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer |
| Q100959565 | Evidence for different molecular parameters in head and neck squamous cell carcinoma of nonsmokers and nondrinkers: Systematic review and meta-analysis on HPV, p16, and TP53 |
| Q33650470 | Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck |
| Q56889832 | Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma |
| Q64926030 | Evolving Treatment Paradigms for Oropharyngeal Squamous Cell Carcinoma. |
| Q47259728 | Excellent response to chemotherapy post immunotherapy |
| Q92608513 | Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors |
| Q87827392 | Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer |
| Q51213139 | Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. |
| Q96950783 | Fewer tumour-specific PD-1+CD8+ TILs in high-risk "Infiltrating" HPV- HNSCC |
| Q47717093 | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. |
| Q54269200 | Frameshift events predict anti-PD-1/L1 response in head and neck cancer. |
| Q45952214 | From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. |
| Q38687552 | Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application? |
| Q90698029 | Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors |
| Q37518341 | Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy |
| Q38971262 | Genomic Approaches to Understanding Response and Resistance to Immunotherapy |
| Q59351932 | Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs |
| Q92179996 | Genomic correlates of response to immune checkpoint blockade |
| Q42380545 | Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. |
| Q47098975 | Genomics and advances towards precision medicine for head and neck squamous cell carcinoma |
| Q47549582 | HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers |
| Q90134450 | HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma |
| Q92276367 | Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma |
| Q46048688 | Head and neck cancer in 2016: A watershed year for improvements in treatment? |
| Q41522410 | Head and neck cancer: improving outcomes with a multidisciplinary approach. |
| Q33607965 | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment |
| Q64062957 | Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy |
| Q60958232 | How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies |
| Q47993949 | How to treat recurrent/metastatic head and neck cancer: the economic issue in real-world practice |
| Q50719954 | Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. |
| Q100391098 | Hyperprogression: A novel response pattern under immunotherapy |
| Q38709131 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. |
| Q50021106 | Immune Checkpoint Blockade: The New Frontier in Cancer Treatment |
| Q56890107 | Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options |
| Q39328076 | Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management |
| Q92950320 | Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy |
| Q91983062 | Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics |
| Q92209204 | Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy |
| Q93270162 | Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma |
| Q91326765 | Immune checkpoint inhibitors and cardiovascular toxicity |
| Q92638791 | Immune checkpoint inhibitors in the treatment of virus-associated cancers |
| Q95933555 | Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma |
| Q47584286 | Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma |
| Q47101155 | Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis |
| Q92980447 | Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma |
| Q30235360 | Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review |
| Q49827315 | Immuno-, radio-, and chemotherapeutic studies in head and neck cancer : Highlights of the ASCO Annual Meeting 2017 |
| Q88497999 | Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough |
| Q45936626 | Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. |
| Q38772744 | Immunogenomics: using genomics to personalize cancer immunotherapy. |
| Q92830547 | Immunohistochemistry-Enabled Precision Medicine |
| Q90326694 | Immunological and classical subtypes of oral premalignant lesions |
| Q52574828 | Immunomethylomics: A Novel Cancer Risk Prediction Tool. |
| Q92127472 | Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells |
| Q64073892 | Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma |
| Q91637388 | Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer |
| Q37730966 | Immunotherapy for Esophageal Squamous Cell Carcinoma |
| Q53704789 | Immunotherapy for Head and Neck Squamous Cell Carcinoma. |
| Q39308337 | Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options |
| Q38736238 | Immunotherapy for head and neck cancer: the future of treatment? |
| Q90428319 | Immunotherapy for head and neck cancer: where are we now and where are we going? |
| Q89420575 | Immunotherapy in Head and Neck Squamous Cell Cancer |
| Q33756244 | Immunotherapy in head and neck cancer: aiming at EXTREME precision |
| Q49557927 | Immunotherapy in head and neck cancer: evidence and perspectives |
| Q45998119 | Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. |
| Q38649914 | Immunotherapy: Who Is Eligible? |
| Q91424525 | Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis |
| Q92030460 | Importance of the immune system in head and neck cancer |
| Q92253369 | In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients |
| Q55106579 | In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. |
| Q47705923 | Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. |
| Q55438940 | Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. |
| Q61817205 | Increased PD-L1 expression in radioresistant HNSCC cell lines after irradiation affects cell proliferation due to inactivation of GSK-3beta |
| Q64120165 | Induction of the Abscopal Effect with Immunotherapy and Palliative Radiation in Metastatic Head and Neck Squamous Cell Carcinoma: A Case Report and Review of the Literature |
| Q33793552 | Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade |
| Q33884361 | Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives |
| Q98464580 | Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck |
| Q91621858 | Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma |
| Q49501422 | Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. |
| Q90568978 | Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma |
| Q64076510 | Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma |
| Q47329066 | Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome |
| Q41854063 | Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? |
| Q38715520 | Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy |
| Q94545882 | Lactate induces PD-L1 in HRASG12V-positive oropharyngeal squamous cell carcinoma |
| Q40242985 | Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer |
| Q50116331 | Leveraging Genomics for Head and Neck Cancer Treatment |
| Q33832752 | Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment |
| Q90478443 | Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab |
| Q37716427 | MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. |
| Q91801415 | Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer |
| Q45873521 | Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). |
| Q37584406 | Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature |
| Q37622998 | Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report |
| Q34541447 | Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix |
| Q52647752 | Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. |
| Q53176144 | Mouse Models for Studying Oral Cancer: Impact in the Era of Cancer Immunotherapy. |
| Q100525979 | Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma |
| Q57494139 | Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor |
| Q48164997 | NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma |
| Q55274460 | Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. |
| Q99555744 | Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models |
| Q47854770 | Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies |
| Q53827700 | New Therapies in Head and Neck Cancer. |
| Q50336126 | New developments in the management of head and neck cancer – impact of pembrolizumab |
| Q47301132 | Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. |
| Q38972343 | Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. |
| Q43164702 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck |
| Q47610092 | Nivolumab in recurrent/metastatic head and neck cancers |
| Q92363011 | Novel Delivery Systems for Checkpoint Inhibitors |
| Q97532341 | Novel Immunotherapeutic Approaches in Head and Neck Cancer |
| Q38635035 | Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck |
| Q47936526 | Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies |
| Q57492388 | On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies |
| Q47368583 | Oral sampling methods are associated with differences in immune marker concentrations |
| Q92086174 | PCR-based zebrafish model for personalised medicine in head and neck cancer |
| Q64977805 | PD-1 Inhibition Minimally Affects Cisplatin-Induced Toxicities in a Murine Model. |
| Q64237924 | PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection |
| Q64903999 | PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. |
| Q41994346 | PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4+ TILs in the presence of PD-L1+ TAMs |
| Q48017207 | PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases |
| Q60960096 | PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection |
| Q55321107 | PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. |
| Q47105638 | PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors |
| Q52723008 | PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. |
| Q64882611 | PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. |
| Q41592956 | PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma |
| Q58561615 | PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade |
| Q39146986 | PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report |
| Q57472982 | Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy |
| Q38861925 | Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients |
| Q90682159 | Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis |
| Q54518660 | Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. |
| Q39193035 | Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. |
| Q64073848 | Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients? |
| Q47641532 | Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population. |
| Q49925686 | Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study |
| Q49036770 | Pembrolizumab for the treatment of bladder cancer |
| Q55253213 | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. |
| Q33757149 | Pembrolizumab in cervical cancer: latest evidence and clinical usefulness |
| Q52881938 | Pembrolizumab in recurrent advanced cervical squamous carcinoma. |
| Q47345366 | Pembrolizumab in the treatment of advanced urothelial cancer |
| Q90224620 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study |
| Q39632681 | Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors |
| Q42375254 | Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. |
| Q64118745 | Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment |
| Q60908672 | Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma |
| Q92801272 | Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors |
| Q55000623 | Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer. |
| Q92060396 | Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date |
| Q55012383 | Precision Medicine in Head and Neck Cancer: Myth or Reality? |
| Q52591781 | Precision Therapy of Head and Neck Squamous Cell Carcinoma. |
| Q97884890 | Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies |
| Q58579220 | Predicting 90-Day Mortality in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma after Curative Surgery |
| Q95591987 | Preface: More than two decades of modern tumor immunology |
| Q89450684 | Preface: More than two decades of modern tumor immunology |
| Q91284516 | Preface: More than two decades of modern tumor immunology |
| Q41041538 | Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination |
| Q96612904 | Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis |
| Q41633683 | Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
| Q92696861 | Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis |
| Q33884484 | Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy |
| Q33788235 | Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis |
| Q47122217 | Programmed cell death ligand 1 as a biomarker in head and neck cancer |
| Q55311366 | Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. |
| Q59805349 | Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers |
| Q49180652 | Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck |
| Q41339254 | Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review |
| Q54723806 | Putting T cells to work-outsourcing neoantigen detection in head and neck cancers? |
| Q56892940 | RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer |
| Q55491553 | Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. |
| Q92306377 | Radioimmunotherapy for the treatment of head and neck cancer |
| Q59606033 | Radiotherapy plus EGFR inhibitors: synergistic modalities. |
| Q52602002 | Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. |
| Q91729359 | Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up |
| Q49797507 | Rational Design for Cervical Cancer Therapeutics: Cellular and Non-Cellular Based Strategies on the Horizon for Recurrent, Metastatic or Refractory Cervical Cancer. |
| Q90440765 | Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma |
| Q64091122 | Real-world systemic therapy treatment patterns for squamous cell carcinoma of the head and neck in Canada |
| Q39107022 | Redirecting the focus of cancer immunotherapy to premalignant conditions |
| Q52725238 | Regulation and Function of the PD-L1 Checkpoint. |
| Q88442150 | Reirradiation of head and neck cancer using modern highly conformal techniques |
| Q41348852 | Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells |
| Q47876963 | Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab. |
| Q64235743 | Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology |
| Q92358620 | Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens |
| Q92538625 | Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion |
| Q58573986 | Routine surveillance scanning in HNSCC: Lung screening CT scans have value but head and neck scans do not |
| Q49902128 | STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy. |
| Q58082830 | Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial |
| Q53837214 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. |
| Q39084242 | Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study |
| Q64066298 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer |
| Q47164715 | Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events |
| Q38809582 | Safety of drug treatments for head and neck cancer |
| Q88654117 | Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study |
| Q90304312 | Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2max ) of >180 Gy for patients with recurrent head and neck cancer |
| Q52655048 | Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype. |
| Q91015143 | Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial |
| Q92632643 | Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review |
| Q52651819 | Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. |
| Q52617485 | Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. |
| Q97539835 | Squamous Cell Carcinoma: An Update on Diagnosis and Treatment |
| Q55457406 | Stereotactic Body Radiotherapy Treatment for Recurrent, Previously Irradiated Head and Neck Cancer. |
| Q91717183 | Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4 |
| Q38971558 | Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC. |
| Q38744053 | Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs |
| Q52596337 | T Cell Dysfunction in Cancer. |
| Q47132997 | T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity |
| Q55644910 | TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. |
| Q64927095 | Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go? |
| Q38851114 | Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies |
| Q49961144 | Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma |
| Q90620359 | Targeting cancer stem cells in squamous cell carcinoma |
| Q38819982 | Targeting the PD-1 pathway in pediatric solid tumors and brain tumors |
| Q39384440 | The "Achilles Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. |
| Q91021396 | The 100 most cited manuscripts in head and neck cancer: a bibliometric analysis |
| Q64084618 | The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer |
| Q38686682 | The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). |
| Q99549310 | The Prognostic Significance of Immune-Related Metabolic Enzyme MTHFD2 in Head and Neck Squamous Cell Carcinoma |
| Q37516448 | The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment |
| Q91895909 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) |
| Q64986397 | The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer. |
| Q92691192 | The changing therapeutic landscape of head and neck cancer |
| Q92767428 | The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis |
| Q38811007 | The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. |
| Q53359622 | The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications. |
| Q52932010 | The latest prospects of investigational drugs for head and neck cancer. |
| Q52678178 | The molecular landscape of head and neck cancer. |
| Q92463703 | The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy |
| Q64052653 | The promise of Immuno-oncology: implications for defining the value of cancer treatment |
| Q89339593 | The promise of immunostimulatory antibodies in head and neck cancer |
| Q54980315 | The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. |
| Q59469171 | The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. |
| Q89046053 | The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck |
| Q50921394 | The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. |
| Q92128972 | The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) |
| Q46518643 | Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. |
| Q50606627 | Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. |
| Q58608193 | Time to abandon single-site irradiation for inducing abscopal effects |
| Q57816910 | Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches |
| Q37664203 | Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies |
| Q99583798 | Translating KEYNOTE-048 into practice recommendations for head and neck cancer |
| Q90300273 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis |
| Q47393365 | Trial watch: Immune checkpoint blockers for cancer therapy |
| Q52681592 | Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. |
| Q89525448 | Tumor immune microenvironment in head and neck cancers |
| Q92199854 | Tumour flare reaction in cancer treatments: a comprehensive literature review |
| Q50545401 | Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma. |
| Q95282869 | Update on oral and oropharyngeal cancer staging - International perspectives |
| Q47095527 | Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017. |
| Q92037447 | Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma |
| Q39194722 | Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response |
| Q38661479 | What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016. |
| Q99632545 | [Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma] |
| Q64979501 | [HPV - A different view on Head and Neck Cancer]. |
| Q51318731 | [Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting]. |
| Q51319375 | [Immunotherapy for HNSCC : Quo vadis?]. |
| Q58606996 | [Immunotherapy highlights of the ASCO annual meeting 2018 for head and neck cancers] |
| Q90322062 | [Oncoimmunology in old age] |
| Q52815753 | [Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment]. |
| Q64889726 | mTOR Signalling in Head and Neck Cancer: Heads Up. |
| Q90688840 | p16 status and choice of chemotherapy in the KEYNOTE-040 study |
Search more.